Trulieve Cannabis Q2 2024 Adj. EPS $0.00 Beats $(0.08) Estimate, Sales $303.000M Beat $293.630M Estimate
Portfolio Pulse from Benzinga Newsdesk
Trulieve Cannabis reported its Q2 2024 results, with an adjusted EPS of $0.00, beating the estimate of $(0.08). Sales were $303.000M, surpassing the expected $293.630M.
August 06, 2024 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trulieve Cannabis reported better-than-expected Q2 2024 results with an adjusted EPS of $0.00 and sales of $303.000M, beating estimates.
The better-than-expected earnings and sales figures are likely to positively impact Trulieve's stock price in the short term. Investors often react favorably to companies that exceed earnings and sales estimates.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100